Skip to main content

Novel treatment
for solid tumours
with no detectable
systemic toxicity

Gordian Pharma is developing MTL-004, a localised therapeutic,
initially targeting glioblastoma (GBM), with potential for
future expansion into additional solid tumours.

About Gordian Pharma Ltd.

Localised Delivery

Direct application to the tumour site to maximise local impact.

Long Lasting Activity

Sustained presence at the treatment site for up to 28 days.

Reduced Systemic Toxicity

No detetable systemic toxicity in studies to date.

Potential for Broad Applications

Applicable across a range of solid tumour indications.